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Abstract
Background: Lower extremity peripheral arterial disease (PAD) is a marker of widespread atherosclerosis.
Individuals with PAD, most of whom do not show typical PAD symptoms (’asymptomatic’ patients), are at
increased risk of cardiovascular ischaemic events. American College of Cardiology/American Heart Association
guidelines recommend that individuals with asymptomatic lower extremity PAD should be identified by
measurement of ankle-brachial index (ABI). However, despite its associated risk, PAD remains under-recognised by
clinicians and the general population and office-based ABI detection is still poorly-known and under-used in
clinical practice. The Prevalence of peripheral Arterial disease in patients with a non-high cardiovascular disease risk,
with No overt vascular Diseases nOR diAbetes mellitus (PANDORA) study has a primary aim of assessing the
prevalence of lower extremity PAD through ABI measurement, in patients at non-high cardiovascular risk, with no
overt cardiovascular diseases (including symptomatic PAD), or diabetes mellitus. Secondary objectives include
documenting the prevalence and treatment of cardiovascular risk factors and the characteristics of both patients
and physicians as possible determinants for PAD under-diagnosis.
Methods/Design: PANDORA is a non-interventional, cross-sectional, pan-European study. It includes approximately
1,000 primary care participating sites, across six European countries (Belgium, France, Greece, Italy, The Netherlands,
Switzerland). Investigator and patient questionnaires will be used to collect both right and left ABI values at rest,
presence of cardiovascular disease risk factors, current pharmacological treatment, and determinants for PAD
under-diagnosis.
Discussion: The PANDORA study will provide important data to estimate the prevalence of asymptomatic PAD in a
population otherwise classified at low or intermediate risk on the basis of current risk scores in a primary care setting.
Trial registration number: Clinical Trials.gov Identifier: NCT00689377.
Background
Lower extremity peripheral arterial disease (PAD) is
considered to be a marker of widespread atherosclerosis.
In patients without overt cardiovascular disease (CVD),
the presence of PAD predicts approximately a 30% risk
of myocardial infarction, ischaemic stroke, and vascular
death over 5 years. Patients with PAD show a 2- to 6-
fold increase in death from cardiovascular causes and a
greater risk of limb amputa t i o nt h a nt h o s ew i t h o u t
PAD. Individuals with PAD also experience higher
1-year rates of cardiovascular death (2.5%) and major
cardiovascular events (21.1%) caused by an increase in
atherothrombotic events, compared with patients with
coronary artery disease (1.9% and 15.2%, respectively) or
with any cerebrovascular disease (2.1% and 14.5%,
respectively) [1-7].
Despite its association with severe health risk, PAD
remains under-recognised by clinicians and the general
population [8,9]. This may be due to the fact that the
majority of individuals with lower extremity PAD do not
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and are considered ‘asymptomatic’. Nevertheless, these
individuals share the unfavourable cardiovascular prog-
nosis of symptomatic patients, as they show a risk profile
comparable to that of patients with symptomatic lower
extremity PAD or with coronary heart disease (CHD)
[1,2,10,11]. Patients diagnosed with PAD, including those
with asymptomatic PAD, should be treated to reach the
recommended therapeutic goals, including low-density
lipoprotein cholesterol (LDL-C) target levels <2.6 mmol/L
(100 mg/dL) [12], which are similar to those recom-
mended for high risk patients, i.e. those with CHD or
CHD risk equivalents - although more challenging than
that recommended for individuals at moderate CVD risk,
i.e. 3.3 mmol/L (130 mg/dL) [2,12,13].
Ankle-brachial index (ABI) value ≤0.90 is the recog-
nised cut-off for diagnosis of PAD. According to a few
observational studies, pathological ABI values are fre-
quently observed among elderly patients (aged 70+ years
or 50-69 years but with a history of cigarette smoking)
who are otherwise not classified as high risk [1,2].
Indeed, the prevalence of a pathological ABI still
remains substantially unknown among patients classified
at intermediate or low risk according to the current risk
scores. The American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines recom-
mend screening for both symptomatic and asympto-
matic PAD, by physical examination and/or ABI
measurement, in order to identify patients with asymp-
tomatic lower limb PAD and to offer appropriate thera-
peutic interventions that diminish risk of myocardial
infarction, stroke, and death.
Hence, the Prevalence of peripheral Arterial disease in
patients with a non-high CVD risk, with No overt vas-
cular Diseases nOR diAbetes mellitus (PANDORA)
study was designed to provide updated information on
the prevalence of PAD, in the context of traditional risk
factor assessment, and insight on clinical characteristics
as possible determinants for PAD under-diagnosis.
Methods/Design
PANDORA is a non-interventional, cross-sectional, pan-
European study of patients with a non-high CVD risk,
defined as having at least two CVD risk factors accord-
ing to National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment
Panel III [ATP III]) guidelines, with no overt CVDs or
diabetes mellitus. Patients with definite symptoms of
PAD will be also excluded (ClinicalTrials.gov Identifier:
NCT00689377).
Approximately 1,000 sites will participate in the study
in six European countries (Belgium, France, Greece,
Italy, The Netherlands, Switzerland). Study objectives
and selection criteria are listed in Table 1. Since the
majority of individuals with a CVD risk factor score of 0
or 1 have a low 10-year risk, i.e. below 10%, these
patients are excluded from the study population [13].
Study variables, as listed in Table 2, are collected in the
Subject Record Form. Data are captured electronically
in most participating countries.
Prior to the inclusion of the first patient, investigators
are requested to complete an Investigator Questionnaire
regarding their personal experience and perception of
the management of CVD risk, and attitude towards
CVD diagnosis, guidelines and goals. The study will col-
lect data on knowledge and behaviour in CVD diagnosis
and management, quantity of CVD cases experienced,
and attitudinal statements about guidelines and goals.
Patients recruited will be asked to complete a Patient
Questionnaire which aims to collect data on awareness
of CVD risk factors, knowledge and awareness of PAD,
CVD risk perception and treatment, frequency of medi-
cal appointments.
The study conforms to the ethical principles outlined
in the Declaration of Helsinki and is consistent with
ICH/Good Clinical Practice, applicable regulatory
requirements, and the AstraZeneca policy on Bioethics.
ABI measurement
Each investigator receives theoretical and practical train-
ing on the ABI measurement technique according to
ACC/AHA guidelines for the management of patients
with PAD [1,2]. Right and left ABI measurement is per-
formed at rest by measuring the systolic blood pressure
from both brachial arteries and from both the dorsalis
pedis and posterior tibial arteries after the patient has
been at rest in the supine position for 10 minutes. Mea-
surements are taken with blood pressure cuffs that are
appropriately sized to the patient’s lower calf (immedi-
ately above the ankle). The hand-held Doppler ultraso-
nography instrument Elite 100R, Nicolet Vascular Inc.
(Golden, Colorado, USA), with an 8 MHz vascular
probe, is used to measure systolic pressures and ABI.
The Elite 100R vascular Doppler device was chosen
since it has been used in major published studies on
PAD detection [1,14]. The 8 MHz probe is preferred
over the 5 MHz probe, due to its higher sensitivity and
reliability in detecting both superficial and deep arteries.
For ABI calculations, the higher of the two brachial
artery systolic pressures, and the higher of the dorsalis
pedis and posterior tibial pressures in each ankle, are
selected. The right and left ABI values are separately
calculated by dividing the higher of the two ankle systo-
lic pressures in that leg by the higher brachial artery sys-
tolic pressure. Calculated ABI values are recorded to
two decimal places. Each patient is considered to have
PAD if ABI in either leg is 0.90 or less [1,2,15].
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Primary objective Secondary objectives
￿ To establish the prevalence of lower extremity PAD, defined as an ABI
≤0.9 in patients with at least two cardiovascular disease (CVD) risk
factors, with no overt CVDs, including typical symptoms of PAD, or
diabetes mellitus
￿ To establish the prevalence of PAD in the context of the cardiovascular
risk level as assessed by the current CVD risk charts or algorithms
￿ To establish the prevalence of CVD risk factors in patients with at least
two CVD risk factors, with no overt CVDs or diabetes mellitus
￿ To establish the risk factor treatment in patients with at least two CVD
risk factors, with no overt CVDs or diabetes mellitus
￿ To identify determinants (i.e. patient and physician characteristics) for
PAD under-diagnosis, defined as the detection of an ABI ≤0.9 in a
patient never diagnosed for PAD
Inclusion criteria Exclusion criteria
￿ Either sex, any race ￿ Fewer than two risk factors for CVD
￿ Males aged ≥45 years or females aged ≥55 years (age-related CVD risk
factor)
￿ Symptoms of PAD
￿ At least one additional risk factor for CVD, from the following: ￿ Type 1 or 2 diabetes mellitus
- cigarette smoking (any amount of tobacco smoked in the past
month)
￿ CHD, including history of myocardial infarction, unstable angina, stable
angina, coronary artery procedures (coronary artery bypass graft or
percutaneous coronary intervention), or evidence of clinically significant
myocardial ischaemia
- arterial blood hypertension (arterial blood pressure: ≥140 mmHg
systolic and/or ≥90 mmHg diastolic or taking antihypertensive
medication)
￿ CHD risk-equivalents, that include clinical manifestations of non-
coronary forms of atherosclerotic disease, i.e. abdominal aortic
aneurysm, or carotid artery disease (transient ischaemic attack or stroke)
- low high-density lipoprotein (HDL) cholesterol (<40 mg/dL,
corresponding to <1.0 mmol/L) or high LDL cholesterol (≥130 mg/
dL, corresponding to ≥3.3 mmol/L), within 3 months of study entry
￿ No blood lipid data collected in the last 12 months
- family history of premature coronary heart disease (CHD) before 55
years of age in father or other male first-degree relative, or before
65 years in mother or other female first-degree relative
￿ Serious or unstable medical or psychological conditions that, in the
opinion of the Investigator, would compromise the patient’s safety or
successful participation in the study
- elevated waist circumference (≥102 cm for male; ≥88 cm for
female)
￿ Patient who is unwilling or unable to provide informed consent
￿ Willingness to participate in the study and complying with the study by
signing a written informed consent
Table 2 Data captured in the Patient Record Form (PRF)
Date of birth, sex, race, civil status
Physical examination, i.e. height, weight, waist circumference, heart pulse, sitting blood pressure
Presence of CVD risk factors
￿ Cigarette/tobacco smoking habits
￿ Physical activity (a physically active patient is defined as an individual performing at least 30 minutes of continuous or intermittent moderate-
intensity exercise 5 days/week)
￿ Alcohol intake
￿ Family history of premature CHD, as defined in Table 1
￿ Arterial blood hypertension, as defined in Table 1
￿ Dyslipidaemia (type of dyslipidaemia; whether untreated or on current lipid-lowering drug treatment)
Lipid data from fasting blood sample taken in the past 12 months (last measure) (date of the blood sample; total cholesterol, HDL cholesterol, and
triglycerides as minimum requirements; LDL cholesterol, glucose, Apo-A1, and Apo-B, if available)
Current pharmacological treatments (drug Anatomical Therapeutic Chemical (ATC) class, duration of treatment, reason for therapy)
Right and left ABI measurement at rest, performed according to American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
for the management of patients with PAD
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The statistical analyses will be descriptive in nature. Data
will be presented as mean ± standard deviation or med-
ian with minimum and maximum. Summary data will be
presented from all available data. Categorical data will be
described by the number and percentage of patients in
each category. Missing observations will be presented in
tables as a separate category. The calculation of propor-
tions will not include the missing category.
The primary objective of this survey is to determine
the proportion of patients with pathological ABI,
according to ACC/AHA guidelines for the management
of patients with PAD. The overall sample size calcula-
tions were based on a confidence interval approach to
ensure that the estimates will have adequate precision.
A reasonable requirement on the precision is that the
incidence should be determined within ± 1%, i.e. the
length of the two-sided 99% confidence should not
exceed 1 percentage value in each direction from the
estimated value. Based on these calculations and expect-
ing a 15% prevalence of individuals with pathological
ABI in the selected population [14], the minimum sam-
p l es i z ec o n s i d e r e ds u f f i c i ent to meet the objectives of
this protocol is 8,454 patients. However, to account for
potential drop-outs, the survey plans to enrol 9,000
patients. Such sample size also ensures that the propor-
tion reporting on the primary endpoint can be estimated
with sufficient precision, on a ‘by-country’ basis, to
represent the country-based heterogeneity of this
population.
Results and discussion
PAD, especially in the asymptomatic stage is common,
and its prompt screening and treatment can reduce car-
diovascular risk [2].
Although PAD shares the same risk factors of other
CVDs and the guidelines recommend the same preven-
tive treatments and therapeutic targets, there is low
awareness of PAD (26% for PAD, compared with 74%
for stroke, and 67% for coronary artery disease and
heart failure, respectively) [8]. There appears to be
greater awareness even of a rare disease such as Lou
Gehrig’s disease (36%), or conditions such as multiple
sclerosis (42%) and cystic fibrosis (29%) [12].
The detection of asymptomatic people with an ABI
≤0.90 allows for the identification of a subgroup at
higher cardiovascular risk than can be determined based
on the usual CVD risk assessment. Diagnosis of asymp-
tomatic PAD in such a population assigns these indivi-
duals to the ‘secondary prevention risk level’ [12].
ABI measurement is now accepted as a simple and reli-
able vascular test to assess leg perfusion. ABI testing is
appropriate in populations targeted from the epidemiolo-
gical database to be at risk for PAD. Among patients with
no history of CVD or diabetes, ABI measurement is
recommended in certain categories appearing to be at
moderate CVD risk, including individuals at higher-risk
ages, and with risk factors typically associated with PAD,
such as cigarette smoking [2]. Quite recently, Cacoub et
al. assessed the prevalence of PAD in a population of
patients with two or more cardiovascular risk factors
[16]. Diehm et al. provided data on the prevalence of
PAD in a large population of unselected individuals aged
≥65 years from the primary care setting [17]. However,
data on the prevalence of asymptomatic PAD in a large
population otherwise classified at low or intermediate
risk are lacking.
Office-based detection of ABI is the most cost-effective
tool for lower extremity PAD detection and provides
o b j e c t i v ed a t ab o t hf o rt h ed i a gnosis in epidemiological
surveys and in-office practice, and monitoring of efficacy
of therapeutic interventions [2,18,19].
ACC/AHA guidelines state that the initial responsibil-
ity for the detection of lower extremity PAD should be
with primary-care providers, because such providers are
best positioned to determine an at-risk population and
to initiate educational, lifestyle, and cardiovascular risk
reduction therapies [2].
Conclusions
Low awareness of PAD and scarce familiarity with the
ABI technique seems to greatly undermine the diagnosis
of asymptomatic PAD patients, who are at comparable
risk to patients with CHD and should be appropriately
treated. Unfortunately, most asymptomatic patients do
not receive a diagnosis of PAD prior to the occurrence
of a morbid or fatal ischaemic disease or event [1,2].
This is particularly true for individuals with asympto-
matic PAD otherwise classified at low or intermediate
risk on the basis of current risk scores. Information on
the prevalence of asymptomatic PAD in such a setting is
lacking. Improving PAD awareness among clinicians and
the public is crucial for effective CVD prevention, early
detection and integrated treatment. The PANDORA
study will provide important pan-European data to esti-
mate the prevalence of asymptomatic PAD in people
with a non-high CVD risk in a primary care setting, by
using the ABI technique, a risk-free gold-standard diag-
nostic test for PAD. This study may provide additional
insights on identifying an at-risk segment of population
that may benefit from appropriate preventive therapy.
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